Although the use of biosimilars in rheumatoid diseases, inflammatory bowel diseases, and oncology has the potential to reduce treatment costs, a variety of factors may influence the adoption of biosimilar treatments.
Capitalizing on our unique expertise in patient chart-based research, we have designed, with input from our clients, a new syndicated offering based on real world data to monitor the impact of biosimilar treatments on inflammatory conditions and cancer patient management.